Edition:
United Kingdom

Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

1.86USD
20 Sep 2018
Change (% chg)

-- (--)
Prev Close
$1.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
161,976
52-wk High
$3.08
52-wk Low
$1.29

Chart for

About

Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating... (more)

Overall

Beta: -0.38
Market Cap(Mil.): $275.67
Shares Outstanding(Mil.): 113.91
Dividend: --
Yield (%): --

Financials

  ATHX.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.26 -- --
ROI: -103.95 1.78 14.61
ROE: -109.33 3.27 16.33

BRIEF-Athersys And Healios Extend By One Month The Period To Complete Collaboration Expansion Agreements

* ATHERSYS AND HEALIOS EXTEND BY ONE MONTH THE PERIOD TO COMPLETE COLLABORATION EXPANSION AGREEMENTS

01 May 2018

BRIEF-Uthealth In Houston And Athersys Announce Funding For Clinical Trial Using Multistem® To Treat Trauma Patients

* UTHEALTH IN HOUSTON AND ATHERSYS ANNOUNCE FUNDING FOR CLINICAL TRIAL USING MULTISTEM® TO TREAT TRAUMA PATIENTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

23 Apr 2018

BRIEF-Healios K.K. Reports 8.7 Pct Stake In Athersys

* HEALIOS K.K. REPORTS 8.7 PERCENT STAKE IN ATHERSYS INC AS OF MARCH 13, 2018 - SEC FILING‍​ Source text: (https://bit.ly/2G0glmi)

23 Mar 2018

Earnings vs. Estimates